Deferasirox

證據等級: L5

預測適應症: 5 個

Deferasirox: From Iron Overload to HIV Infectious Disease

One-Sentence Summary

Deferasirox is a selective oral iron chelator, approved globally for treating chronic iron overload caused by repeated blood transfusions in patients with conditions such as thalassemia and sickle cell disease. The TxGNN model predicts it may be effective for HIV Infectious Disease, with 0 clinical trials and 2 publications currently supporting this direction — both limited to basic mechanistic research.

Quick Overview

Item	Content
Original Indication	Chronic iron overload (transfusional hemosiderosis)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.40%
Evidence Level	L4
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this dataset. Based on published pharmacology, deferasirox is a trivalent-selective oral iron chelator (Fe³⁺) that forms a stable 2:1 complex with iron and promotes its excretion primarily via feces. Its efficacy in reducing systemic iron burden in transfusion-dependent patients is well-established across multiple global regulatory approvals, even though Saudi Arabia has no registered authorization.

The mechanistic rationale connecting iron chelation to HIV involves iron's role as an essential cofactor in viral biology. HIV-1 replication depends on adequate intracellular iron availability at multiple steps, and endolysosomal iron specifically regulates the activity of HIV-1 Tat — a key transactivator protein that drives expression of the entire viral genome via the LTR promoter. A 2021 in vitro study demonstrated that higher endolysosomal iron promotes Tat-mediated LTR transactivation, while iron restriction increases Tat oligomerization and β-catenin expression, effectively limiting HIV-1 gene activation. This suggests that by chelating available iron, deferasirox could theoretically disrupt a critical step in the HIV replication cycle.

However, this connection remains a mechanistic hypothesis derived entirely from cell culture experiments. No animal models have been tested, no dose-response data exist for this application, and no clinical trials have evaluated deferasirox as an anti-HIV agent. The prediction is biologically plausible but sits squarely in early exploratory territory.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34550543	2021	Basic Research	Journal of Neurovirology	Endolysosomal iron promotes HIV-1 Tat-mediated LTR transactivation; iron restriction increases Tat oligomerization and β-catenin expression, potentially limiting HIV-1 replication — in vitro mechanism study relevant to HAND pathogenesis
16529348	2006	Drug Review	J Am Pharmacists Assoc	Pharmacist-oriented review of deferasirox at the time of its original approval; documents the drug's properties but does not address HIV

Saudi Arabia Market Information

Deferasirox has no registered market authorizations in Saudi Arabia. The drug is marketed in other regions (e.g., Exjade® / Jadenu®) but has not obtained SFDA approval as of the data cutoff date.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in this evidence pack. The TFDA package insert was retrieved during data collection but its contents were not parsed into the current dataset. Deferasirox is known to carry important renal and hepatic monitoring requirements — these should be reviewed from the originator's approved labeling before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The iron-HIV mechanistic link is biologically plausible — iron availability influences HIV-1 Tat activity and viral replication — but the entire evidence base consists of a single 2021 in vitro study. There are no clinical trials, no animal model data, and no observational studies evaluating deferasirox in HIV patients. This is a hypothesis worth tracking, not a repurposing candidate ready for development planning.

To proceed, the following is needed:

Full safety profile: package insert warnings, contraindications, and known drug interactions (particularly relevant given HIV patients typically take complex antiretroviral regimens)
At least one in vivo (animal) study confirming iron chelation reduces HIV viral load or delays disease progression
Pharmacokinetic modeling to establish whether clinically safe deferasirox doses can achieve intracellular iron reduction sufficient to meaningfully inhibit HIV-1 replication
Assessment of immune-function trade-offs: iron is also required for T-cell proliferation and innate immunity; chelation in an already immunocompromised population carries theoretical risk
Review of deferasirox's potential for drug-drug interactions with antiretrovirals (e.g., via CYP450 or UGT pathways)
Consideration of the rank-2 prediction (chronic HCV infection), which has a more established clinical rationale — iron overload management in thalassemia + HCV co-infection — and may represent a nearer-term research opportunity
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.